Drug Profile
Anti CD19 chimeric antigen receptor T cell therapy - HRAIN Biotechnology
Alternative Names: Anti-CD19 CAR-T Cell Therapy - HRAIN Biotechnology; DSCAR-01Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Hrain Biotechnology
- Developer Fudan University Zhongshan Hospital; HRAIN Biotechnology; Shanghai Changzheng Hospital; Shanghai General Hospital; Shanghai Jiaotong University School of Medicine; Xuzhou Medical University
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-Hodgkin's lymphoma
- Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma
- No development reported Mantle-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
- 23 Feb 2022 Phase-I/II trial is still ongoing for Diffuse large B cell lymphoma (Second-line therapy or greater) in China (IV) (ChiCTR1800017686)
- 23 Feb 2022 Phase-I/II trial is still ongoing for Follicular lymphoma (Second-line therapy or greater) in China (IV) (ChiCTR1800017686)